Our leadership team believes that successful drug discovery requires focused collaboration, which we execute by working with our scientists and clinicians on unique populations and novel genomics. We actively seek collaborations with companies and foundations in order to leverage and complement resources and capabilities.
Meet the Director
Paul J. Kenny, PhD, is the Director of the Experimental Therapeutics Institute and the Ward-Coleman Professor and Chair of the Dorothy H. and Lewis Rosenstiel Department of Pharmacology and Systems Therapeutics at the Icahn School of Medicine at Mount Sinai. Dr. Kenny is a world renowned researcher in the neurobiology of obesity and drug addiction. He has considerable drug development expertise and is one of only a handful of researchers in the United States who has had a drug licensed from an academic institution.
Dr. Kenny’s multidisciplinary research involves the study of behavioral paradigms, physiological analyses, and the molecular underpinnings of neurobehavioral disorders. He is actively investigating the brains of rodents to uncover new signaling cascades that may play a role in addiction-like behaviors.
Meet the Associate Director
Louise Lammers, PhD, is the Associate Director of Operations and the Senior Program Manager for 4D Technology Development at the Center for Technology, Innovation, and Entrepreneurship at the Icahn School of Medicine at Mount Sinai. Dr. Lammers came to Mount Sinai in 2012, after moving to the United States from the Netherlands. In the Netherlands, she started and managed a pre-competitive research program at TI Pharma that enables and runs pharmaceutical research partnerships between industry and academia. Prior to TI Pharma, she worked for Philips Electronics in several R&D management roles in Europe and Asia. Dr. Lammers was a post-doctoral fellow at the Delft University of Technology in the Netherlands, and received a PhD in structural chemistry from the University of Cape Town in South Africa.